Cari Gallman, executive vice president, general counsel and chief policy officer, leads Law, Public Policy & Government Affairs at Bristol Myers Squibb, overseeing intellectual property, commercial and regulatory law, litigation, corporate governance, transactions, compliance & ethics and corporate security. She is also responsible for our global policy and government affairs teams where she oversees our strategy around critical policy issues affecting the company and the people we serve.
“In a constantly evolving healthcare landscape, we have a responsibility to safeguard the interests of patients by helping shape a dynamic policy environment—one that is grounded in ethical decision-making and designed to enable innovation, expand access and deliver lasting impact. When we do both well, we not only protect what matters most today—we help create the conditions for progress tomorrow.”
Cari joined Bristol Myers Squibb in 2015 as an attorney and held increasing roles of responsibility until 2020, when she was named as the chief compliance and ethics officer where she drove efforts to ensure our operations are always conducted in compliance with ethical business practices and championed our Principles of Integrity. In 2023, she was appointed the head of Corporate Affairs, where she advanced our company strategy through strategic communications, government relations and policy, corporate social responsibility, corporate marketing and brand reputation, and patient advocacy.
Prior to BMS, Cari began her legal career in private practice representing pharmaceutical and medical device manufacturers in government enforcement and regulatory matters. In her practice, she regularly advised companies on how to design and implement robust compliance policies to meet business objectives as well as legal needs.
She earned a bachelor’s degree in political theory from Princeton University, magna cum laude, and a JD from Harvard Law School.
This person is not in any offices
Bristol-Myers Squibb
229 followers
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.